Nephrogenic systemic fibrosis

Vasa - Journal of Vascular Diseases

Volumn 38, Issue 1, 2009, Pages 31-38

  Vosshenrich, Rolf ^a   Reimer, P ^b  

^a Radiologen Gemeinschaftspraxis   (Germany)

^b STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Gadolinium; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Renal failure

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOTERIOL; GADOVERSETAMIDE; GADOXETIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; PENTOXIFYLLINE; SODIUM THIOSULFATE; THALIDOMIDE; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CHRONIC LIVER DISEASE; COMORBIDITY; DIALYSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG STABILITY; ENDOTHELIUM INJURY; EOSINOPHILIA MYALGIA SYNDROME; EOSINOPHILIC FASCIITIS; ERYTHEMA; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; KIDNEY DISEASE; KIDNEY FUNCTION; LACTATION; LIPODERMATOSCLEROSIS; METABOLIC ACIDOSIS; MORPHEA; NAUSEA AND VOMITING; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLARITY; PAIN; PATHOGENESIS; PERITONEAL DIALYSIS; PHYSICAL CHEMISTRY; PHYSIOTHERAPY; PREGNANCY; PRURITUS; PUVA; REVIEW; RISK FACTOR; SCLERODERMA; SCLEROMYXEDEMA; SKIN BIOPSY; SWELLING; SYMPTOMATOLOGY; THROMBOSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISCOSITY; BIOPSY; HISTORY; KIDNEY FAILURE; PATHOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; SKIN;

BIOPSY; CONTRAST MEDIA; GADOLINIUM DTPA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SKIN;

EID: 71049155021     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.38.1.31     Document Type: Review

References (41)

1. Baron PW, Cantos K, Hillebrandt DJ et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis.Am J Dermatolpathol 2003; 25(3): 204-9.
2. Bellin MF. MR contrast agents: the old and the new. Eu J Radiol 2006; 314-23.
3. Bongartz G,Mayr M, Bilecen D. Magnetic resonance angiography (MRA) in renal impairerd patients:When an how.Eur J Radiol 2008; doi.1016/ j.ejrad.2008.01.031.
4. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56(1):27-30.
5. Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004; 150(3): 596-7.
6. Cowper SE,Robin HS, Steinberg SM, et al. Scleromyxedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356(9234): 1000-1.
7. Cowper SE, Su L, Robin H, et al. Nephrogenic fibrosing dermopathy. Am J Dermopathol 2001; 23(5): 383-93.
8. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006; 8(2): 151-7.
9. Cowper SE.Nephrogenic fibrosing dermopathy [NFD7NSF Web site]. 2001-2007. Available at: http://www.icnfdr.org [Accessed January 02, 2007].
10. Cowper SE. Nephrogenic systemic a review and exploration of the role of gadolinium. Advances in Dermatology 2007; 23: 131-54.
11. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; doi. 1016/ j.ejrad.200801.016.
12. Daram SR, Cortese CM, Bastani M. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review.Am J Kidney Dis 2005; 45: 754-9.
13. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dail 2006; 19: 191-4.
14. European medicines agency. Available at: http://www.emea.europa.eu.
15. European society of magnetic resonance in medicine and biology. Available at: http://www.esmrmb.org.
16. European society of urogenital radiology. ESUR guideline on contrast media.Version 6.0.2007 www.esur.org.
17. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21(4): 1104-8.
18. Hubbard V, Davenport A, Jarmulowicz M, et al. Sceromyxedema-like change in four renal dialysis patients. Br J Dermatol 2003; 148(3): 563-8.
19. Idee J-M, Port M, Rayant I. Schaefer M, Greneur SL, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fund Clinl Pharmacol 2006; 20: 563-76.
20. Kirchin MA, Priovano GP, Spinazzi A. Gadobenate dimeg lumine (Gd-BOPTA): an overview. Invest Radiol 1998; 33: 798-809.
21. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006; 41: 491-9.
22. Kubik-Huch RA, Goldstein-Aalame NM, Frenzel Th, Seifert B, Puchert E, Wittek S, Debatin J. Gadopentetate Dimeglumine Excretion into Human Breast Milk during Lactation. Radiology 2000; 216: 555-8.
23. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003; 139(7): 928-30.
24. Lin SP, Brown JJ. MR contrast agents: Physical and pharmacologic basics. J Magn Reson Imaging 2007; 25: 884-99.
25. Linfert DR, Schell JO, Fine DM. Treatment of nephrogenic systemic fibrosis: limited options but hope for the future.Seminars in Dialysis 2008 doi.10.1111/J.1525-139x.2007.00407.x
26. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used fpr contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.
27. Marcos SK. Extracellular gadolnium contrast agents: differences in stability. Eur J Radiol 2008; doi.10.1016/j.erad.2008.01.25.
28. Mc Neill Am, Barr RJ. Sceromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol 2002; 41(6): 364-7.
29. Moschella SI, Kay J,Mackool BT, Liu V. case records of the Massachusetts General Hospital.Weekly clinicopathological excercises. Case 35-2004.A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004; 351: 2219-27.
30. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Mag Reson Med 1991; 22: 222-8.
31. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathologic hypothesis. Br J Dermatol 2004; 150(5): 1050-2.
32. Pieringer H, Schmekal B, Jako O, Biesenbach G. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3094.
33. Public Health Advisory. Update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. Dermopathy [US FDA Web site]. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm [Accessed January 02, 207].
34. Rapp JH,Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in pateints with known or suspected peripheral arterial disease: safety and efficacy of gadofosveset-enhanced MR angiography. Multicenter comparative phase III study. Radiology 2006; 236: 71-8.
35. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.Eur Radiol 2004; 14: 559-78.
36. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathological features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 2003; 48: 42-7.
37. Thomsen HS. ESUR guideline: gadolinium-based contrast media and nephrogenic fibrosis. Eur Radiol 2007; 17: 2992-6.
38. Thomsen HS,Marckmann P. Introduction. Eur J Radiol 2008; doi.10.1016/ j.ejrad.2008.01.22.
39. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6.
40. Webb JA, Thomsen HS, Marcos SK. The use of iodinated and gadolinium contrast media during pregnancy and lactation.Eur Radiol 2005; 15: 1234-40.
41. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of GBCbased contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2: 258-63.